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Abstract: 
Tumorous growth often faces hypoxic (low oxygen tension) conditions and the adaptations of these cells to hypoxic 
conditions determine their survival. The cancer cells respond to hypoxia by altering the expression of different genes 
and Hypoxia-Inducible Factor (HIF)-1 is one of it. HIF-1 is a transcriptional factor that response to hypoxia (low 
oxygen tension) conditions quickly. Expression of HIF-1 gene is essential for increase in vascularization of hypoxic 
region such as tumor and thus aid in proliferation and survival of cancerous cells. Moreover, HIF-1 signaling in 
cancer cells has a diverse influence on the metastatic cascade. Targeting HIF-1 is therefore one of the most 
promising approach to treat cancer. In this review, we have focused on the potential of targeting HIF-1 pathway as 
therapeutic intervention to treat cancer. 
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INTRODUCTION: 
Hypoxia is the deficiency either in the delivery or the 
utilization of oxygen at the cellular level, which can 
alter various physiological functions of the cells, with 
severe consequences to the organism. In humans, the 
hypoxic conditions occur during various 
pathophysiological conditions, like tumorous growth, 
myocardial ischemia, stroke etc [1] [2] [3]. When 
cells sense a decrease hypoxia, they develop adaptive 
responses in order to sustain this condition and 
survive. If hypoxia lasts too long or is too severe, the 
cells eventually die [4]. Interestingly, tumorous 
growths often face hypoxic conditions and the 
adaptations of these cells to hypoxic conditions 
determine the prognostic potential of the tumors. 
Indeed, it has also been shown that hypoxia 
contributes to the selection of cells with decreased 
apoptotic potential and high metastatic capability [5]. 
The cells respond to hypoxia by altering the 
expression of various genes and most important one 
is HIF-1 [6].  
One of the important signaling pathways activated 
during hypoxia conditions in cancer cells is HIF-1 
signaling. HIF-1 is a heterodimeric consists of α-
subunit (oxygen-regulated) and β-subunit 
(constitutively expressed). The HIF-1α subunit is 
oxygen sensitive due to the presence of an oxygen-
dependent degradation (ODD) domain. Under normal 
conditions, prolyl hydroxylases hydroxylate HIF-1 α 
subunit at proline residues and triggers their 
proteasomal degradation [7] [8] [9] [10]. But under 
hypoxia conditions, HIF-α is stabilizes and 
translocated to nucleus, as prolyl hydroxylases are 
inhibited. Within nucleus HIF-α dimerize and bind to 
hypoxia-responsive elements (HREs) of allow their 
expression. It should be noted here that HIF-1 allows 
expression of 100s of genes and thus boost cellular 
capacity to survive in hypoxia environment (see 
figure 1). The microenvironment around the 
tumorous area is highly hypoxic, but activation of 
HIF-1 allows proliferation of such tumors by 
enhancing angiogenesis. Increased angiogenesis 
increases oxygen supply to the cancerous area and 
therefore promote their growth [11] [12]. So based on 
its central role in survival of cancer cells, 
manipulation of HIF-1 activity in tumor masses has 
emerged as a focus now-a-days to develop 
pharmaceutical and noninvasive treatment, as an 
alternate options for cancer patients.  
 
 
 
Fig. 1: Shows activation of HIF-1 pathway: During hypoxia stress, HIF1-α gets stabilize and is tranlocated to 
nucleus, where it dimerizes with HIF1-ß to form a complex. The dimer recognizes the HREs on the target genes and 
allows their expression.  
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Table 1: Human cancers exhibiting increased levels of HIF-1 protein. 
_____________________________________________________________________________________ 
Cancer type              References 
Bladder cancer [13] 
Breast [14] 
Cervical cancer [15] 
Colon cancer [16] 
Colorectal cancer [17] 
Endometrial cancer [18] 
Esophageal Squamous cell carcinoma (SCC) [19] 
Gastrointestinal stromal tumor [20] 
Glioma [21] 
Head and neck SCC [22] 
Laryngeal cancer [23] 
Liver cancer [24] 
Lung cancer [25] 
Melanoma [26] 
Oligodendroglioma [27] 
Ovarian cancer [28] 
Prostate cancer [29] 
Renal cancer [30] 
 
Proper oxygen (O2) supply is required by the 
mammalian cells to grow, proliferate and to maintain 
aerobic metabolism properly. However in tumor cells 
O2 supply is impaired due to decrease in O2 delivery 
and diffusion and therefore hypoxic condition is 
created. Hypoxia is considered as a prominent 
characteristic feature in the tumor tissue which drives 
aggressiveness of a tumor mass [31]. It should be 
noted here that the cancer cells counter this hypoxia 
conditions by activating HIF-1 pathway, which inturn 
modify the cellular environment to combat the 
hypoxic stress condition. HIF-1 plays a central role in 
hypoxia and is therefore considered to be an essential 
protein in tumor proliferation [32]. The expression 
level of HIF-1 is increased in different tumor tissues 
and positively correlates with tumor aggressiveness 
and poor prognosis (see table 1). To further support 
the role of HIF -1 in cancer progression, it has been 
found that loss of HIF-1α function is associated with 
the decrease in tumor growth, vascularization, and 
metastasis.  
 
As earlier stated, HIF-1 activation is responsible for 
the tumor progression, and therefore inhibiting its 
activation could be used as a therapeutic approach in 
cancer. However, the HIF-1 pathway is a highly 
complex mechanism and involves activation of a 
diverse proteins, each of which may serve target to in 
an anti cancer therapy approach [33]. Down 
regulation of HIF-1 protein is considered to be the 
main strategy that could be attained via activation of 
hydroxylases. Actually such hydroxylases belong to 
the 2-oxoglutarate (2OG)-dependent oxygenase 
superfamily and require a ferrous ion, as a cofactor 
for activation. Treatment of cells with iron and 
ascorbate has been found to decline HIF-1 protein 
levels and its target genes [34]. Till date, many types 
of HIF-1 inhibitors have been discovered and some 
are under clinical trials. Each inhibitor act via a 
specific mode of action to manipulate HIF-1 pathway 
and some of the inhibitors are mentioned here. 
Echinomycin, nutlin-3 and bortezomib inhibit the 
HIF-1-mediated gene expressions [35] [36] [37]. 
Microtubule disruptors, HSP90 inhibitors, and YC-1 
destabilize HIF-1α in the post-translational level [38] 
[39] [40]. Some other agents such as topotecan, 
digoxin, PX-478, rapamycin and chaetocin block de 
novo synthesis of HIF-1α protein [41] [42] [43] [44] 
[45]. Similarly HIF-1α inhibition by using siRNA in 
vivo and in vitro has been reported to decreased 
growth and metastasis of cancerous cells [46] [47] 
[48]. More and more understanding of the HIF-1 
domains like their structure and molecular biology 
will result in unearthing therapeutic molecules.  
 
CONCLUSION: 
Hypoxia is a well known phenomenon in solid tumor 
masses due to insufficient vascularization. Cancer 
cells activate HIF-1 pathway to deal with this O2 
stress, which inturn support a vast number of cellular 
processes. As HIF-1 protein has a well known role in 
supporting growth and proliferation of cancerous 
cells and therefore its targeting has emerged an 
alternate way to deal with the tumor growth. It should 
be noted here that till date no specific HIF-1α 
inhibitor has been approved clinically, although 
different anti cancer drugs are in use that indirectly 
affect the HIF-1 pathway. Due to its central role in 
supporting growth and metastasis of tumor cell, it is 
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promising that in near future specific HIF-1α 
inhibitors will be developed and clinically approved. 
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